nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ABCB1—Lisinopril—dilated cardiomyopathy	0.184	0.532	CbGbCtD
Mefloquine—ABCB1—Spironolactone—dilated cardiomyopathy	0.162	0.468	CbGbCtD
Mefloquine—Flecainide—SCN5A—dilated cardiomyopathy	0.0419	1	CrCbGaD
Mefloquine—Appetite absent—Lisinopril—dilated cardiomyopathy	0.009	0.0209	CcSEcCtD
Mefloquine—Blister—Furosemide—dilated cardiomyopathy	0.00828	0.0192	CcSEcCtD
Mefloquine—Ataxia—Spironolactone—dilated cardiomyopathy	0.00749	0.0174	CcSEcCtD
Mefloquine—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00717	0.0167	CcSEcCtD
Mefloquine—Drug interaction—Furosemide—dilated cardiomyopathy	0.00643	0.0149	CcSEcCtD
Mefloquine—Hearing impaired—Furosemide—dilated cardiomyopathy	0.00627	0.0146	CcSEcCtD
Mefloquine—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.00627	0.0146	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00608	0.0141	CcSEcCtD
Mefloquine—Renal failure—Spironolactone—dilated cardiomyopathy	0.00603	0.014	CcSEcCtD
Mefloquine—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00573	0.0133	CcSEcCtD
Mefloquine—Memory impairment—Lisinopril—dilated cardiomyopathy	0.00571	0.0132	CcSEcCtD
Mefloquine—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.0056	0.013	CcSEcCtD
Mefloquine—HBA1—Folate Metabolism—GPX1—dilated cardiomyopathy	0.00533	0.0295	CbGpPWpGaD
Mefloquine—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00521	0.0121	CcSEcCtD
Mefloquine—Alopecia—Spironolactone—dilated cardiomyopathy	0.00487	0.0113	CcSEcCtD
Mefloquine—Deafness—Furosemide—dilated cardiomyopathy	0.00484	0.0112	CcSEcCtD
Mefloquine—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00483	0.0112	CcSEcCtD
Mefloquine—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00476	0.0111	CcSEcCtD
Mefloquine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00461	0.0107	CcSEcCtD
Mefloquine—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00453	0.0105	CcSEcCtD
Mefloquine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00445	0.0103	CcSEcCtD
Mefloquine—HBA1—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.00444	0.0246	CbGpPWpGaD
Mefloquine—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00435	0.0101	CcSEcCtD
Mefloquine—Malaise—Spironolactone—dilated cardiomyopathy	0.00432	0.01	CcSEcCtD
Mefloquine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00429	0.00997	CcSEcCtD
Mefloquine—HBA1—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.00423	0.0234	CbGpPWpGaD
Mefloquine—Neuropathy—Lisinopril—dilated cardiomyopathy	0.0042	0.00976	CcSEcCtD
Mefloquine—Irritability—Furosemide—dilated cardiomyopathy	0.00414	0.0096	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00407	0.0225	CbGpPWpGaD
Mefloquine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00403	0.00937	CcSEcCtD
Mefloquine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00395	0.00916	CcSEcCtD
Mefloquine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00391	0.00909	CcSEcCtD
Mefloquine—Cramp muscle—Furosemide—dilated cardiomyopathy	0.0039	0.00906	CcSEcCtD
Mefloquine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00383	0.0089	CcSEcCtD
Mefloquine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00382	0.00887	CcSEcCtD
Mefloquine—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00376	0.00872	CcSEcCtD
Mefloquine—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00362	0.0084	CcSEcCtD
Mefloquine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00348	0.00808	CcSEcCtD
Mefloquine—ACHE—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.00346	0.0192	CbGpPWpGaD
Mefloquine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00338	0.00785	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00331	0.00769	CcSEcCtD
Mefloquine—Renal failure—Furosemide—dilated cardiomyopathy	0.00328	0.00762	CcSEcCtD
Mefloquine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00323	0.00749	CcSEcCtD
Mefloquine—Sweating—Furosemide—dilated cardiomyopathy	0.0032	0.00743	CcSEcCtD
Mefloquine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00316	0.00733	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00314	0.0174	CbGpPWpGaD
Mefloquine—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00312	0.00724	CcSEcCtD
Mefloquine—Urticaria—Spironolactone—dilated cardiomyopathy	0.00311	0.00722	CcSEcCtD
Mefloquine—Irritability—Lisinopril—dilated cardiomyopathy	0.0031	0.00721	CcSEcCtD
Mefloquine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00309	0.00719	CcSEcCtD
Mefloquine—BCHE—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.00309	0.0171	CbGpPWpGaD
Mefloquine—Ataxia—Lisinopril—dilated cardiomyopathy	0.00306	0.0071	CcSEcCtD
Mefloquine—ACHE—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00302	0.0167	CbGpPWpGaD
Mefloquine—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00293	0.0068	CcSEcCtD
Mefloquine—Visual impairment—Furosemide—dilated cardiomyopathy	0.00289	0.00671	CcSEcCtD
Mefloquine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00288	0.0067	CcSEcCtD
Mefloquine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00283	0.00658	CcSEcCtD
Mefloquine—Eye disorder—Furosemide—dilated cardiomyopathy	0.0028	0.0065	CcSEcCtD
Mefloquine—Tinnitus—Furosemide—dilated cardiomyopathy	0.00279	0.00649	CcSEcCtD
Mefloquine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00277	0.00643	CcSEcCtD
Mefloquine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00272	0.00632	CcSEcCtD
Mefloquine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00268	0.00622	CcSEcCtD
Mefloquine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00261	0.00606	CcSEcCtD
Mefloquine—Erythema—Furosemide—dilated cardiomyopathy	0.00261	0.00606	CcSEcCtD
Mefloquine—HBA1—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	0.0026	0.0144	CbGpPWpGaD
Mefloquine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00259	0.00601	CcSEcCtD
Mefloquine—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00252	0.00585	CcSEcCtD
Mefloquine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00251	0.00583	CcSEcCtD
Mefloquine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00249	0.00578	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00248	0.00577	CcSEcCtD
Mefloquine—Rash—Spironolactone—dilated cardiomyopathy	0.00247	0.00573	CcSEcCtD
Mefloquine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00247	0.00573	CcSEcCtD
Mefloquine—Renal failure—Lisinopril—dilated cardiomyopathy	0.00246	0.00572	CcSEcCtD
Mefloquine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00246	0.00571	CcSEcCtD
Mefloquine—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00246	0.0057	CcSEcCtD
Mefloquine—Headache—Spironolactone—dilated cardiomyopathy	0.00245	0.00569	CcSEcCtD
Mefloquine—HBA2—Metabolism—ANKRD1—dilated cardiomyopathy	0.00242	0.0134	CbGpPWpGaD
Mefloquine—ACHE—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.00242	0.0134	CbGpPWpGaD
Mefloquine—Sweating—Lisinopril—dilated cardiomyopathy	0.0024	0.00558	CcSEcCtD
Mefloquine—Agitation—Furosemide—dilated cardiomyopathy	0.0024	0.00557	CcSEcCtD
Mefloquine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00237	0.0055	CcSEcCtD
Mefloquine—Vertigo—Furosemide—dilated cardiomyopathy	0.00234	0.00544	CcSEcCtD
Mefloquine—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00234	0.00543	CcSEcCtD
Mefloquine—Leukopenia—Furosemide—dilated cardiomyopathy	0.00234	0.00542	CcSEcCtD
Mefloquine—Nausea—Spironolactone—dilated cardiomyopathy	0.00232	0.0054	CcSEcCtD
Mefloquine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00229	0.00532	CcSEcCtD
Mefloquine—HBA2—Metabolism—TAZ—dilated cardiomyopathy	0.00227	0.0126	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00225	0.0125	CbGpPWpGaD
Mefloquine—Hallucination—Lisinopril—dilated cardiomyopathy	0.00224	0.0052	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00221	0.00512	CcSEcCtD
Mefloquine—BCHE—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.00215	0.0119	CbGpPWpGaD
Mefloquine—Confusional state—Furosemide—dilated cardiomyopathy	0.00215	0.00499	CcSEcCtD
Mefloquine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00213	0.00495	CcSEcCtD
Mefloquine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00213	0.00494	CcSEcCtD
Mefloquine—HBA1—Folate Metabolism—TNF—dilated cardiomyopathy	0.00212	0.0117	CbGpPWpGaD
Mefloquine—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00211	0.0117	CbGpPWpGaD
Mefloquine—ADORA2A—Monoamine Transport—AGT—dilated cardiomyopathy	0.0021	0.0116	CbGpPWpGaD
Mefloquine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.0021	0.00487	CcSEcCtD
Mefloquine—Shock—Furosemide—dilated cardiomyopathy	0.00209	0.00487	CcSEcCtD
Mefloquine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00209	0.00485	CcSEcCtD
Mefloquine—Flushing—Lisinopril—dilated cardiomyopathy	0.00209	0.00485	CcSEcCtD
Mefloquine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00208	0.00484	CcSEcCtD
Mefloquine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00207	0.0048	CcSEcCtD
Mefloquine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00206	0.00478	CcSEcCtD
Mefloquine—HBA2—Metabolism—SDHA—dilated cardiomyopathy	0.00206	0.0114	CbGpPWpGaD
Mefloquine—CYP19A1—FSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00204	0.0113	CbGpPWpGaD
Mefloquine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00204	0.00474	CcSEcCtD
Mefloquine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00203	0.00471	CcSEcCtD
Mefloquine—Chills—Lisinopril—dilated cardiomyopathy	0.00202	0.00469	CcSEcCtD
Mefloquine—Hypotension—Furosemide—dilated cardiomyopathy	0.00199	0.00462	CcSEcCtD
Mefloquine—Alopecia—Lisinopril—dilated cardiomyopathy	0.00199	0.00461	CcSEcCtD
Mefloquine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00197	0.00458	CcSEcCtD
Mefloquine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00196	0.00455	CcSEcCtD
Mefloquine—Erythema—Lisinopril—dilated cardiomyopathy	0.00196	0.00455	CcSEcCtD
Mefloquine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00191	0.00444	CcSEcCtD
Mefloquine—Somnolence—Furosemide—dilated cardiomyopathy	0.00189	0.0044	CcSEcCtD
Mefloquine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00188	0.00437	CcSEcCtD
Mefloquine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00185	0.0043	CcSEcCtD
Mefloquine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00184	0.00428	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00184	0.00427	CcSEcCtD
Mefloquine—Fatigue—Furosemide—dilated cardiomyopathy	0.00184	0.00426	CcSEcCtD
Mefloquine—Tremor—Lisinopril—dilated cardiomyopathy	0.00183	0.00426	CcSEcCtD
Mefloquine—HBA1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00183	0.0101	CbGpPWpGaD
Mefloquine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00182	0.00422	CcSEcCtD
Mefloquine—Malaise—Lisinopril—dilated cardiomyopathy	0.00177	0.0041	CcSEcCtD
Mefloquine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00176	0.00408	CcSEcCtD
Mefloquine—Syncope—Lisinopril—dilated cardiomyopathy	0.00176	0.00408	CcSEcCtD
Mefloquine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00175	0.00408	CcSEcCtD
Mefloquine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00175	0.00407	CcSEcCtD
Mefloquine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00174	0.00404	CcSEcCtD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00174	0.00962	CbGpPWpGaD
Mefloquine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00173	0.00402	CcSEcCtD
Mefloquine—HBA1—Metabolism—TAZ—dilated cardiomyopathy	0.00172	0.00954	CbGpPWpGaD
Mefloquine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00172	0.004	CcSEcCtD
Mefloquine—Urticaria—Furosemide—dilated cardiomyopathy	0.00169	0.00393	CcSEcCtD
Mefloquine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00168	0.00391	CcSEcCtD
Mefloquine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00168	0.00391	CcSEcCtD
Mefloquine—HBA1—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	0.00168	0.00931	CbGpPWpGaD
Mefloquine—ACHE—Monoamine Transport—AGT—dilated cardiomyopathy	0.00168	0.00927	CbGpPWpGaD
Mefloquine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00167	0.00387	CcSEcCtD
Mefloquine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00167	0.00387	CcSEcCtD
Mefloquine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00167	0.00387	CcSEcCtD
Mefloquine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00166	0.00386	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00166	0.00384	CcSEcCtD
Mefloquine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00165	0.00382	CcSEcCtD
Mefloquine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00161	0.00374	CcSEcCtD
Mefloquine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.0016	0.00371	CcSEcCtD
Mefloquine—Oedema—Lisinopril—dilated cardiomyopathy	0.0016	0.00371	CcSEcCtD
Mefloquine—Shock—Lisinopril—dilated cardiomyopathy	0.00157	0.00365	CcSEcCtD
Mefloquine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00157	0.00364	CcSEcCtD
Mefloquine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00156	0.00363	CcSEcCtD
Mefloquine—ADORA2A—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00156	0.00864	CbGpPWpGaD
Mefloquine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00156	0.00362	CcSEcCtD
Mefloquine—HBA1—Metabolism—SDHA—dilated cardiomyopathy	0.00156	0.00863	CbGpPWpGaD
Mefloquine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00155	0.0036	CcSEcCtD
Mefloquine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00154	0.00359	CcSEcCtD
Mefloquine—Asthenia—Furosemide—dilated cardiomyopathy	0.00153	0.00355	CcSEcCtD
Mefloquine—Pruritus—Furosemide—dilated cardiomyopathy	0.00151	0.0035	CcSEcCtD
Mefloquine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00149	0.00347	CcSEcCtD
Mefloquine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00146	0.00338	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00146	0.00338	CcSEcCtD
Mefloquine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00144	0.00336	CcSEcCtD
Mefloquine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00143	0.00333	CcSEcCtD
Mefloquine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00142	0.00331	CcSEcCtD
Mefloquine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00142	0.0033	CcSEcCtD
Mefloquine—Dizziness—Furosemide—dilated cardiomyopathy	0.00141	0.00327	CcSEcCtD
Mefloquine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00141	0.00327	CcSEcCtD
Mefloquine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00139	0.00323	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00138	0.0032	CcSEcCtD
Mefloquine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00138	0.0032	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00137	0.0076	CbGpPWpGaD
Mefloquine—Vomiting—Furosemide—dilated cardiomyopathy	0.00135	0.00314	CcSEcCtD
Mefloquine—Rash—Furosemide—dilated cardiomyopathy	0.00134	0.00312	CcSEcCtD
Mefloquine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00134	0.00312	CcSEcCtD
Mefloquine—Headache—Furosemide—dilated cardiomyopathy	0.00133	0.0031	CcSEcCtD
Mefloquine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00132	0.00306	CcSEcCtD
Mefloquine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00131	0.00303	CcSEcCtD
Mefloquine—Urticaria—Lisinopril—dilated cardiomyopathy	0.00127	0.00295	CcSEcCtD
Mefloquine—Nausea—Furosemide—dilated cardiomyopathy	0.00126	0.00294	CcSEcCtD
Mefloquine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00126	0.00293	CcSEcCtD
Mefloquine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00126	0.00293	CcSEcCtD
Mefloquine—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00124	0.00685	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.00123	0.00678	CbGpPWpGaD
Mefloquine—CYP19A1—FSH signaling pathway—RAF1—dilated cardiomyopathy	0.00122	0.00677	CbGpPWpGaD
Mefloquine—ACHE—Peptide hormone metabolism—ACE—dilated cardiomyopathy	0.00121	0.00669	CbGpPWpGaD
Mefloquine—ADORA2A—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.00118	0.00653	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00118	0.00653	CbGpPWpGaD
Mefloquine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00118	0.00273	CcSEcCtD
Mefloquine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00115	0.00266	CcSEcCtD
Mefloquine—Pruritus—Lisinopril—dilated cardiomyopathy	0.00113	0.00263	CcSEcCtD
Mefloquine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00109	0.00254	CcSEcCtD
Mefloquine—BCHE—Peptide hormone metabolism—ACE—dilated cardiomyopathy	0.00108	0.00597	CbGpPWpGaD
Mefloquine—Dizziness—Lisinopril—dilated cardiomyopathy	0.00106	0.00245	CcSEcCtD
Mefloquine—BCHE—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00105	0.00582	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00102	0.00564	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00102	0.00564	CbGpPWpGaD
Mefloquine—Vomiting—Lisinopril—dilated cardiomyopathy	0.00102	0.00236	CcSEcCtD
Mefloquine—Rash—Lisinopril—dilated cardiomyopathy	0.00101	0.00234	CcSEcCtD
Mefloquine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00101	0.00234	CcSEcCtD
Mefloquine—Headache—Lisinopril—dilated cardiomyopathy	0.001	0.00232	CcSEcCtD
Mefloquine—ADORA2A—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000957	0.00529	CbGpPWpGaD
Mefloquine—ADORA2A—Monoamine Transport—TNF—dilated cardiomyopathy	0.000951	0.00526	CbGpPWpGaD
Mefloquine—Nausea—Lisinopril—dilated cardiomyopathy	0.000949	0.0022	CcSEcCtD
Mefloquine—ADORA1—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000947	0.00524	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000945	0.00523	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—ABCC9—dilated cardiomyopathy	0.000943	0.00522	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—ACTN2—dilated cardiomyopathy	0.000904	0.005	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000879	0.00486	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000851	0.00471	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—ABCC9—dilated cardiomyopathy	0.000841	0.00465	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000827	0.00458	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00081	0.00448	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00081	0.00448	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—ACTN2—dilated cardiomyopathy	0.000806	0.00446	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000778	0.0043	CbGpPWpGaD
Mefloquine—ACHE—Peptide hormone metabolism—AGT—dilated cardiomyopathy	0.000767	0.00424	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00076	0.00421	CbGpPWpGaD
Mefloquine—ACHE—Monoamine Transport—TNF—dilated cardiomyopathy	0.000759	0.0042	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.000757	0.00419	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000753	0.00417	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000738	0.00408	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00073	0.00404	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000729	0.00404	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000727	0.00402	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000715	0.00395	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000694	0.00384	CbGpPWpGaD
Mefloquine—ADORA1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00069	0.00382	CbGpPWpGaD
Mefloquine—BCHE—Peptide hormone metabolism—AGT—dilated cardiomyopathy	0.000684	0.00379	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000678	0.00375	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.000672	0.00372	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.000672	0.00372	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000667	0.00369	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000657	0.00364	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000625	0.00346	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000625	0.00346	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000623	0.00345	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000617	0.00341	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000617	0.00341	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.000599	0.00332	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.000599	0.00332	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000598	0.00331	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000591	0.00327	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000581	0.00322	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000573	0.00317	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000563	0.00312	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000561	0.00311	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—GPX1—dilated cardiomyopathy	0.000559	0.00309	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000555	0.00307	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000551	0.00305	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—CD36—dilated cardiomyopathy	0.000544	0.00301	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000532	0.00295	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000515	0.00285	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000503	0.00278	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—AGT—dilated cardiomyopathy	0.00049	0.00271	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000481	0.00266	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000476	0.00263	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000476	0.00263	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000474	0.00262	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000466	0.00258	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000456	0.00252	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00045	0.00249	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000444	0.00246	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000443	0.00245	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000438	0.00242	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000429	0.00237	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000428	0.00237	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—GPX1—dilated cardiomyopathy	0.000423	0.00234	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000421	0.00233	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00042	0.00232	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—CD36—dilated cardiomyopathy	0.000412	0.00228	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000392	0.00217	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000381	0.00211	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000378	0.00209	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—AGT—dilated cardiomyopathy	0.000371	0.00205	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ANKRD1—dilated cardiomyopathy	0.000368	0.00204	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000366	0.00203	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000348	0.00193	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000348	0.00193	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000347	0.00192	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—TAZ—dilated cardiomyopathy	0.000346	0.00192	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000338	0.00187	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000338	0.00187	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000334	0.00185	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ANKRD1—dilated cardiomyopathy	0.000329	0.00182	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000328	0.00182	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000324	0.00179	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—TAZ—dilated cardiomyopathy	0.000318	0.00176	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000316	0.00175	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000316	0.00175	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000314	0.00174	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—SDHA—dilated cardiomyopathy	0.000313	0.00173	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—TAZ—dilated cardiomyopathy	0.000309	0.00171	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000294	0.00163	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—SDHA—dilated cardiomyopathy	0.000288	0.00159	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000285	0.00158	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—SDHA—dilated cardiomyopathy	0.000279	0.00155	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000278	0.00154	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000269	0.00149	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000269	0.00149	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000268	0.00149	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000268	0.00148	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.000265	0.00146	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000258	0.00143	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000254	0.00141	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000252	0.0014	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00025	0.00138	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000244	0.00135	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000244	0.00135	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000244	0.00135	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000243	0.00135	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000242	0.00134	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000239	0.00132	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000237	0.00131	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000237	0.00131	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.000236	0.00131	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000231	0.00128	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—ACE—dilated cardiomyopathy	0.000228	0.00126	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000227	0.00126	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000225	0.00125	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000221	0.00122	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00022	0.00122	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000212	0.00117	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000211	0.00117	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000207	0.00115	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—RAF1—dilated cardiomyopathy	0.000206	0.00114	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—ACE—dilated cardiomyopathy	0.000204	0.00113	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000197	0.00109	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000196	0.00109	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000193	0.00107	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000191	0.00106	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000191	0.00106	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000189	0.00104	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000188	0.00104	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000187	0.00103	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000187	0.00103	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000186	0.00103	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000186	0.00103	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—RAF1—dilated cardiomyopathy	0.000183	0.00102	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000183	0.00101	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000182	0.00101	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000179	0.000992	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000178	0.000986	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000176	0.000972	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000174	0.000962	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000173	0.000958	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000171	0.000948	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000171	0.000946	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.00017	0.000943	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000168	0.000932	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000168	0.000927	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000166	0.000919	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000163	0.0009	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.00016	0.000888	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00016	0.000887	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000154	0.000852	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000152	0.000843	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000151	0.000836	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000151	0.000834	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000149	0.000827	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000146	0.000806	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000145	0.000801	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000144	0.000799	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000144	0.000799	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000144	0.000796	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000142	0.000786	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000138	0.000766	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000136	0.000755	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000136	0.000754	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000134	0.000743	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000132	0.000732	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.00013	0.000719	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000129	0.000715	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000128	0.000711	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000121	0.000671	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000119	0.000658	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000117	0.000649	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000111	0.000614	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000106	0.000586	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000105	0.000583	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AGT—dilated cardiomyopathy	0.000101	0.00056	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	9.88e-05	0.000547	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	9.29e-05	0.000514	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.18e-05	0.000508	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.05e-05	0.000501	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GPX1—dilated cardiomyopathy	8.51e-05	0.000471	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	8.4e-05	0.000465	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	8.31e-05	0.00046	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CD36—dilated cardiomyopathy	8.29e-05	0.000459	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	8.17e-05	0.000452	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.15e-05	0.000451	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	7.91e-05	0.000438	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GPX1—dilated cardiomyopathy	7.82e-05	0.000433	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AGT—dilated cardiomyopathy	7.81e-05	0.000432	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CD36—dilated cardiomyopathy	7.61e-05	0.000421	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GPX1—dilated cardiomyopathy	7.59e-05	0.00042	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AGT—dilated cardiomyopathy	7.46e-05	0.000413	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CD36—dilated cardiomyopathy	7.39e-05	0.000409	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RAF1—dilated cardiomyopathy	7.02e-05	0.000389	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AGT—dilated cardiomyopathy	6.86e-05	0.000379	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AGT—dilated cardiomyopathy	6.66e-05	0.000368	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.29e-05	0.000348	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	5.42e-05	0.0003	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—dilated cardiomyopathy	4.81e-05	0.000266	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.81e-05	0.000266	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.72e-05	0.000206	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3.7e-05	0.000205	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	3.61e-05	0.0002	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	3.49e-05	0.000193	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	3.4e-05	0.000188	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	3.25e-05	0.00018	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	3.06e-05	0.000169	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.28e-05	0.000126	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.22e-05	0.000123	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2e-05	0.000111	CbGpPWpGaD
